Trial Opens In Glaxo's Lamictal Patent Suit

Law360, New York (January 18, 2005, 12:00 AM EST) -- U.K. drug maker GlaxoSmithKline Plc’s patent lawsuit against Israeli generics maker Teva Pharmaceutical Industries Ltd. over its best-selling anti-epileptic drug Lamictal will be heard in a U.S. court on Tuesday.

The trial, in the U.S. District Court for the U.S. District of New Jersey, is expected to last between five and seven days. A decision in the case is not expected until much later in the year.

Last July, Chief Judge John W. Bissell of the District of New Jersey granted summary judgment in favor of...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.